Cover storyCDMO Trends 2026: What’s Driving Mergers And Acquisitions
CDMO trends 2026 show a structural consolidation wave — bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.
Cover storyCDMO trends 2026 show a structural consolidation wave — bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.

Merck and Moderna's mRNA cancer vaccine hits Phase 3 primary endpoint, raising immediate GMP and cold-chain scale-up questions for personalized biologics.

Cadila Pharma appoints Surender Narain Singh as VP of Business Development, signalling a push into regulated export markets.

EC approves J&J's teclistamab plus daratumumab for second-line RRMM, backed by Phase 3 OS data, raising supply and GMP implications for combination biologics.

Ipsen closes Kartos Therapeutics acquisition, adding Phase III MDM2 inhibitor navtemadlin for myelofibrosis to its oncology pipeline.
Latest edition

Sep 28
Feb 03From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.








Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
